Ginkgo Bioworks Holdings, Inc.
DNAGinkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company that specializes in organism engineering and synthetic biology. By designing and programming custom microbes, Ginkgo aims to develop sustainable solutions across industries such as agriculture, pharmaceuticals, food, and specialty chemicals. The firm leverages automation, data, and engineering to accelerate biological research and product development.
Company News
A-Alpha Bio, a biotechnology company using synthetic biology and machine learning, has hired Troy Lionberger as Chief Business Officer to lead business development and expand partnerships across biopharma and adjacent sectors.
The microbial fermentation technology market is experiencing significant growth, driven by the increasing incidence of chronic diseases and the growing demand for cutting-edge treatments. North America is expected to dominate the market during the forecast period.
The global synthetic biology market is projected to grow from $19.3 billion in 2024 to $61.6 billion by 2029, driven by applications in healthcare, agriculture, and the environment. Factors driving growth include increasing R&D funding, declining DNA sequencing costs, and continuous innovations.
Nanorobots, tiny machines ranging from 1 to 100 nanometers in size, are revolutionizing healthcare by enabling targeted drug delivery, cellular repair, and early disease detection. The global nanorobots market in healthcare is rapidly expanding, driven by advancements in nanotechnology and increasing investments in research and development.
The global nanobots in healthcare market is expected to grow at a CAGR of 8.6% during 2025-2030, driven by advancements in nanotechnology, increasing prevalence of chronic diseases, and growing demand for minimally invasive surgeries. Nanorobots are revolutionizing healthcare by offering new possibilities in diagnostics, targeted drug delivery, a...
